Catalent Invests $4.6M To Further Expand Asia–Pacific Clinical Trials
News Feb 05, 2016
Company has announced that it will invest $4.6M to further expand its Singapore clinical supply facility by building new flexible GMP space for secondary packaging, doubling its ambient storage space, and quadrupling cold storage capacity. The continued expansion of the site will support global and regional customers’ growth in clinical trials activity in the Asia–Pacific region.
Established in 1998, Catalent’s Singapore site now provides full clinical supply services including project and supply chain management, comparator sourcing, clinical label printing, secondary packaging, clinical storage, import/export management, Importer of Record (IoR) service, and full returns and destruction management services. It has served as a key regional hub for studies in Australia, Singapore, Korea, Hong Kong and other countries in Southeast Asia.
“Our Singapore facility is fully approved by the Health Science Authority for GMP across all its activities,” commented Wetteny Joseph, Catalent’s President of Clinical Supply Services. “Customer demand at the site has increased by 30% over last year, and this expansion, coupled with our recently announced opening of a facility in Japan, will allow Catalent to better support multinational customers’ growing trial’s needs, while providing more flexible solutions for local customers in the region.”
With facilities in the US, UK, Germany, Japan and China, and an extended network of over 50 audited depots, Catalent’s clinical supply services team has the capability and expertise to handle a broad range of international compliance and distribution requirements, that can help to expedite clinical trials and ensure that customers are reliably supplied where and when needed around the globe.
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Anti-Malaria Drugs Delivered With CaffeineNews
Many drug delivery systems, such as capsules and tablets, can be difficult to swallow, especially for children. Making delivery systems out of polymer gels is an attractive option, but usually requires hazardous levels of heavy metals to be used. Now, scientists have found a way to build these gels from caffeine molecules.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018